Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00630812 · ClinicalTrials.gov registry record · Phase 3
Long Term Administration of Inhaled Mannitol in Cystic Fibrosis
A Phase 3 study of Cystic Fibrosis, sponsored by Syntara.
- Completed
- Registry status
- Phase 3
- Development phase
- 318
- Enrollment target
- 20
- Study locations
NCT00630812 is a Phase 3 study of Cystic Fibrosis that has completed, run by Syntara. The registered enrollment target is 318 participants, above the 177-participant average among 169 other Cystic Fibrosis trials with a reported enrollment target (80% higher). The trial reports 20 study locations across 18 states.
The verdict
NCT00630812, a Phase 3 study of Cystic Fibrosis, has completed, sponsored by Syntara.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 318 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to examine the efficacy and safety of 26 weeks treatment with inhaled mannitol in subjects with cystic fibrosis. Previous studies have demonstrated improvements in lung function, mucociliary clearance, changes in physical properties of mucus, 24 hour sputum weight and quality of life. The results of this study are to further investigate and confirm these findings in addition to examine the effect on antibiotic use and chest infections. It is hypothesised that inhaled mannitol will have beneficial effects compared to a control treatment. An open label phase of 26 weeks duration will follow the blinded 26 week phase. During the open label phase all subjects will receive active treatment.
Conditions Studied
Interventions
- DRUG Placebo comparator
- DRUG inhaled mannitol
Study Locations (20)
Florida
- Nemours Childrens Clinic - Jacksonville
- Batchelor Children's Research Institute - University of Miami - Miami
- Nemours Children's Clinic Orlando - Orlando
Arizona
- University of Arizona - Tucson
Connecticut
- Central Connecticut Cystic Fibrosis Center - Hartford
Idaho
- St Lukes CF Center of Idaho - Idaho City
Illinois
- Northwestern Memorial Hospital - Chicago
Louisiana
- Louisiana State University Health Sciences Center - Shreveport
Maine
- Maine Pediatric Specialty Group - Portland
Maryland
- John Hopkins - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 318 participants |
| Start Date | 2008-09 |
| Est. Completion | 2010-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00630812
The ClinicalTrials.gov registry entry for NCT00630812 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 318 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 177-participant average among 169 other Cystic Fibrosis trials with a reported enrollment target (80% higher). The listed sponsor is Syntara, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Cystic Fibrosis appearing as the primary indexed condition, and to 2 interventions - of which Placebo comparator is the first listed.
NCT00630812 reports 20 study locations spanning 18 distinct geographic areas - top geographies include Florida, Arizona, Connecticut.
Frequently Asked Questions
What is clinical trial NCT00630812 about?
NCT00630812 is a clinical study titled "Long Term Administration of Inhaled Mannitol in Cystic Fibrosis". The purpose of this study is to examine the efficacy and safety of 26 weeks treatment with inhaled mannitol in subjects with cystic fibrosis. Previous studies have demonstrated improvements in lung function, mucociliary clearance, changes in physical properties of mucus, 24 hour sputum weight and qu...
What is the current status of trial NCT00630812?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 318 participants. The study started on 2008-09. Estimated completion is 2010-11.
What conditions does trial NCT00630812 study?
This clinical trial studies the following conditions: Cystic Fibrosis.
What interventions are being tested in trial NCT00630812?
The interventions under investigation include: Placebo comparator (DRUG), inhaled mannitol (DRUG).
Who is sponsoring clinical trial NCT00630812?
This trial is sponsored by Syntara, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00630812 being conducted?
This trial has 20 study locations across Arizona, Connecticut, Florida, Idaho, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cystic Fibrosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Assessing Tenapanor as a Treatment of CF-related Constipation.
RECRUITING · Phase 3
-
Evaluation of VX-121/Tezacaftor/Deutivacaftor in Cystic Fibrosis (CF) Participants 1 Through 11 Years of Age
RECRUITING · Phase 3
-
A Study Evaluating the Long-term Safety and Efficacy of VX-121 Combination Therapy
ACTIVE NOT RECRUITING · Phase 3
-
Safety of Tobramycin Inhalation Powder (TIP) vs Tobramycin Solution for Inhalation in Patients With Cystic Fibrosis
COMPLETED · Phase 3
-
Study of Ataluren (PTC124™) in Cystic Fibrosis
COMPLETED · Phase 3
-
Study to Evaluate Lumacaftor and Ivacaftor Combination Therapy in Subjects 12 Years and Older With Advanced Lung Disease
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.